实用癌症杂志
實用癌癥雜誌
실용암증잡지
THE PRACTICAL JOURNAL OF CANCER
2015年
4期
559-562
,共4页
晚期肾癌%DC-CIK%化疗%淋巴细胞亚群%细胞因子
晚期腎癌%DC-CIK%化療%淋巴細胞亞群%細胞因子
만기신암%DC-CIK%화료%림파세포아군%세포인자
Advanced renal cell carcinoma%DC-CIK%Chemotherapy%Lymphocyte subsets%Cytokines
目的：探讨DC-CIK联合化疗在治疗晚期肾癌患者中的综合应用价值。方法回顾性分析接受化疗的46例晚期肾癌病例，其中21例联合DC-CIK治疗（ DC-CIK组），25例仅接受化疗（化疗组）。比较2组间肿瘤生长情况、患者长期生存情况、不良反应发生情况等差异；并对外周血淋巴细胞亚群和细胞因子水平进行检测，比较组间差异。结果DC-CIK组实体瘤近期缓解情况显著优于化疗组；DC-CIK组中位总生存时间为20个月、1年生存率为90．48％，显著高于化疗组的17个月、84．00％，P＜0．05。治疗1、3个疗程后DC-CIK组CD3＋、CD4＋、CD8＋比例显著高于化疗组，IL-2、IL-12、IFN-γ含量显著高于化疗组，P＜0．05。结论 DC-CIK联合化疗能有效提高晚期肾癌患者的免疫能力，促进IL-2、IL-12、IFN-γ等细胞因子的表达，从而发挥杀死肿瘤细胞、缓解实体瘤、延长患者生存期的功效。
目的：探討DC-CIK聯閤化療在治療晚期腎癌患者中的綜閤應用價值。方法迴顧性分析接受化療的46例晚期腎癌病例，其中21例聯閤DC-CIK治療（ DC-CIK組），25例僅接受化療（化療組）。比較2組間腫瘤生長情況、患者長期生存情況、不良反應髮生情況等差異；併對外週血淋巴細胞亞群和細胞因子水平進行檢測，比較組間差異。結果DC-CIK組實體瘤近期緩解情況顯著優于化療組；DC-CIK組中位總生存時間為20箇月、1年生存率為90．48％，顯著高于化療組的17箇月、84．00％，P＜0．05。治療1、3箇療程後DC-CIK組CD3＋、CD4＋、CD8＋比例顯著高于化療組，IL-2、IL-12、IFN-γ含量顯著高于化療組，P＜0．05。結論 DC-CIK聯閤化療能有效提高晚期腎癌患者的免疫能力，促進IL-2、IL-12、IFN-γ等細胞因子的錶達，從而髮揮殺死腫瘤細胞、緩解實體瘤、延長患者生存期的功效。
목적：탐토DC-CIK연합화료재치료만기신암환자중적종합응용개치。방법회고성분석접수화료적46례만기신암병례，기중21례연합DC-CIK치료（ DC-CIK조），25례부접수화료（화료조）。비교2조간종류생장정황、환자장기생존정황、불량반응발생정황등차이；병대외주혈림파세포아군화세포인자수평진행검측，비교조간차이。결과DC-CIK조실체류근기완해정황현저우우화료조；DC-CIK조중위총생존시간위20개월、1년생존솔위90．48％，현저고우화료조적17개월、84．00％，P＜0．05。치료1、3개료정후DC-CIK조CD3＋、CD4＋、CD8＋비례현저고우화료조，IL-2、IL-12、IFN-γ함량현저고우화료조，P＜0．05。결론 DC-CIK연합화료능유효제고만기신암환자적면역능력，촉진IL-2、IL-12、IFN-γ등세포인자적표체，종이발휘살사종류세포、완해실체류、연장환자생존기적공효。
Objective To study the comprehensive application value of DC-CIK combined with chemotherapy for ad-vanced renal cell carcinoma.Methods Retrospective analysis of 46 cases of patients with advanced renal cell carcinoma was conducted,21 cases received DC-CIK therapy (DC-CIK group),25 cases received chemotherapy (chemotherapy group).Tumor growth,long-term survival and adverse reactions of the 2 groups were compared;and the levels of peripheral blood lymphocyte sub-sets and cytokine of the 2 groups were detected and compared.Results The solid tumor remission in the DC-CIK group was bet-ter than that of the chemotherapy group,and the median overall survival time and the 1-year survival rate of the DC-CIK group were respectively 20 months and 90.48%,which were higher than those of the chemotherapy group 17 months,84.00%,P<0.05.After 1,3 courses of treatment,the percentages of CD3+,CD4+,CD8+of the DC-CIK group were higher than that of the chemotherapy group;and the serum levels of IL-2,IL-12,IFN-γof the DC-CIK group were higher than that of the chemotherapy group,all P<0.05.Conclusion DC-CIK combined with chemotherapy can effectively improve the immunity of patients with ad-vanced renal cell carcinoma,promote the expression of cytokines such as IL-2,IL-12,IFN-γand so on,so as to kill tumor cells, relieve solid tumor and improve survival of patients.
